menu
    • menu
    [{"orgOrder":0,"company":"Tilray","sponsor":"Tilray","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tilray \/ Tilray","highestDevelopmentStatusID":"10","companyTruncated":"Tilray \/ Tilray"},{"orgOrder":0,"company":"Tilray","sponsor":"IntelGenx","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Tilray \/ Tilray","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Tilray"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Sleep","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oil","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Aphria","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Strip","sponsorNew":"Tilray \/ Aphria","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Aphria"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||Cannabinoid CB1 receptor","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Tilray \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Tilray \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Tilray \/ University of British Columbia"},{"orgOrder":0,"company":"Tilray","sponsor":"Tilray","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"TIL-TC150","moa":"T-cell","graph1":"Neurology","graph2":"Phase I","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Tilray \/ Tilray","highestDevelopmentStatusID":"6","companyTruncated":"Tilray \/ Tilray"}]

    Find Clinical Drug Pipeline Developments & Deals by Tilray

    Menu

    Tilray

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tilray Medical Shares Positive Oral Cannabis Extract Data for Chemotherapy-Induced Emesis

                            Details : Tilray Medical aimed to test the effectiveness of an oral cannabis extract in adults suffering from chemotherapy-induced nausea and vomiting despite standard anti-nausea treatments.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            November 07, 2024

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tilray Medical Granted Approval to Introduce Third Medical Cannabis Product in Portugal

                            Details : Tilray's oral solution THC10:CBD10 medical cannabis extract is approved for medical use in Portugal for various medical conditions including chronic pain, nausea and spasticity.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            July 24, 2024

                            Lead Product(s) : Tetrahydrocannabinol,Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : IntelGenx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilr...

                            Details : The agreement aims for the co-development and commercialization of cannabinoid-infused VersaFilm® products, including CBD VersaFilm (cannabinoid), a unique drug opportunity for the treatment of neurodegenerative diseases of the brain.

                            Product Name : CBD VersaFilm

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            November 06, 2023

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : IntelGenx

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tilray Medical Launches New Products and ‘CannaPoints’ Program to Support Patients Across Canada

                            Details : Tilray Medical, has released new medical cannabis products, under Tilray and Aphria brands and launched CannaPoints, a new program designed to support patients through their medical cannabis journey.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 25, 2022

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tilray Medical Launches Sleep-Oriented CBN Night Oil for Medical Cannabis Patients in Canada

                            Details : CBN, or cannabinol, is derived from THC and is known to help improve the duration and quality of sleep, CBN-dominant oil is carefully formulated with 30mg CBN per mL and 10mg THC per mL (in a 50mL bottle).

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 07, 2022

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Aphria

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Launch of Tilray’s Fast-Acting Oral Strips Highlights Commitment to Medical Cannabis Innovation and Patient ...

                            Details : Company's Fast-Acting Oral Strips contain Cannabinoids absorb directly into the bloodstream provide patients with a fast-acting, convenient, and precise dosing experience for relief from a range of conditions.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            December 02, 2021

                            Lead Product(s) : Cannabidiol,Tetrahydrocannabinol

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Aphria

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : McMaster University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study

                            Details : Cannabidiol is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Generalized Anxiety Disorder.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 08, 2018

                            Lead Product(s) : Cannabidiol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : McMaster University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TIL-TC150

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Recipient : The Hospital for Sick Children

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cannabinoid Therapy for Pediatric Epilepsy

                            Details : TIL-TC150 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Epilepsy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 06, 2016

                            Lead Product(s) : TIL-TC150

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Recipient : The Hospital for Sick Children

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            Tilray

                            Canada arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : University of British Columbia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder

                            Details : Tetrahydrocannabinol is a Controlled Substance drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            August 07, 2015

                            Lead Product(s) : Tetrahydrocannabinol

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : University of British Columbia

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth